Center-Authored Papers

Filters: Author is Sosman, Jeffrey A  [Clear All Filters]
2017
Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER et al..  2017.  CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.. European urology. Abstract
2016
Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J et al..  2016.  Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.. Cancer immunology research. 4(11):959-967. Abstract
2015
McDermott DF, Cheng S-C, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS et al..  2015.  The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 21(3):561-8. Abstract
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER et al..  2015.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.. The New England journal of medicine. 373(19):1803-1813. Abstract
2014
Carson WE, Unger JM, Sosman JA, Flaherty LE, Tuthill R, Porter MJ, Thompson JA, Kempf RA, Othus M, Ribas A et al..  2014.  Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-negative Melanoma: Long-Term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival.. Cancer immunology research. Abstract
2012
Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL, Othus M, Sosman JA, Kirkwood JM, Sondak VK.  2012.  Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (SWOG S0438).. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(4):1129-1137. Abstract